Novo Nordisk is doubling down on the race for oral weight‑loss drugs, cutting a blockbuster partnership with Boston startup Vivtex that could channel up to $2.1 billion into the local company if development milestones are met. The deal leans on Vivtex’s robotics, AI and living‑tissue “gut‑on‑a‑chip” screening system to help turn injectable biologics into pills, underscoring how the battle for GLP‑1 and next‑generation obesity medicines is shifting toward pill‑friendly platforms.
Deal details
In a press release, GlobeNewswire reported that Vivtex will license select oral drug‑delivery technologies while Novo Nordisk will take the lead on global development, regulatory filings, manufacturing and commercialization. According to the company, Vivtex will receive an undisclosed guaranteed upfront payment and is also eligible for research funding, milestone payments that could total up to $2.1 billion, plus tiered royalties on any future product sales.
Vivtex’s local roots and technology
Vivtex was cofounded by MIT scientists Robert Langer, Giovanni Traverso and Thomas von Erlach and operates out of the Boston Globe’s old Morrissey Boulevard building in Dorchester, according to The Boston Globe. The company says its platform combines high‑throughput robotic screening, living‑tissue “gut‑on‑a‑chip” assays and AI modelling to identify oral formulations that can survive the gastrointestinal tract, per the firm’s website. Vivtex also notes that it already works with several pharma partners as it hunts for oral candidates to treat obesity and diabetes.
Pill push and price moves
The Vivtex deal lands shortly after Novo Nordisk rolled out a Wegovy pill in early January, a milestone reported by The Washington Post. Novo has also said it will lower list prices for Wegovy and Ozempic to $675 a month beginning Jan. 1, 2027, according to reporting by Fox Business.
Where the market is headed
Big pharma is speeding up external deals to move oral obesity drugs along faster. In January, Boston‑based Nimbus signed a collaboration with Eli Lilly that could be worth up to $1.3 billion, according to Reuters. Investors have punished Novo Nordisk amid competitive pressure and trial setbacks, and analysts say partnerships like the Vivtex agreement are one way to buy technical capability and time, per reporting by BioPharma Dive.
What to watch next
All eyes will be on which molecules Novo Nordisk selects and whether Vivtex’s formulations make it into human testing. Any success could lower manufacturing costs for oral biologics and widen patient access. For Boston, the deal is another reminder that the region’s science can translate into marquee partnerships with major drugmakers, a storyline local investors and life‑science watchers will be following closely.
